TXLNA

Across TCGA pan-cancer cohorts, TXLNA mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TXLNA’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where TXLNA mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TXLNA is over-expressed in tumor.

HNSC, CCRCC, and COAD are the cancer types where TXLNA tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TXLNA mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	+0.445	<.001	11	view →
CCRCC	All	III,IV	+0.223	<.001	11	view →
COAD	Female	All	+0.418	<.001	10	view →
LUAD	Female	III,IV	+0.612	<.001	9	view →
LSCC	Male	All	+0.366	<.001	8	view →
OV	All	All	+0.326	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TXLNA–HNSC

Open the HNSC breakdown →